As the pandemic rages on, doctors across the country are beginning to notice a trend. A number of children who have contracted COVID-19 have also been impacted by a rare…
As reported in a press release in PR Newswire; in Stockholm this week, Dan Kastner received the Crafoord Prize, one of the top achievements in science worldwide, after his work…
Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…
Ionis and the University of California, San Diego (UCSD) have formed a team to investigate antisense oligonucleotide technology as a treatment for multiple myeloma. Their drug, ION251, has shown positive…
The COVID pandemic affecting eighty-million children in the nation has been a burden on many families. A number that deserves attention is the seven million students who have learning disabilities.…
Dr. Andrew Brunner, an oncologist at Massachusetts Cancer Center was recently interviewed by Targeted Oncology. The discussion centered around a phase 1b clinical trial (NCT03066648) investigating sabatolimab together with hypomethylating…
What are neuromuscular junctions and how do they play a role in the development of Charcot-Marie-Tooth disease (CMT)? According to Charcot-Marie-Tooth News, researchers discovered that structural neuromuscular junction changes caused…
A team of German Scientists is offering hope for people who have sports, traffic, or war-related injuries of the spinal cord. According to a recent article in Neuroscience News, these…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
